These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32189324)

  • 1. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
    Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
    Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
    Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
    Karnes JH; Rettie AE; Somogyi AA; Huddart R; Fohner AE; Formea CM; Ta Michael Lee M; Llerena A; Whirl-Carrillo M; Klein TE; Phillips EJ; Mintzer S; Gaedigk A; Caudle KE; Callaghan JT
    Clin Pharmacol Ther; 2021 Feb; 109(2):302-309. PubMed ID: 32779747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of pharmacogenetics in clinical practice: problems and solutions.
    Baskys A
    J Neural Transm (Vienna); 2019 Jan; 126(1):109-113. PubMed ID: 29922908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
    Caudle KE; Rettie AE; Whirl-Carrillo M; Smith LH; Mintzer S; Lee MT; Klein TE; Callaghan JT;
    Clin Pharmacol Ther; 2014 Nov; 96(5):542-8. PubMed ID: 25099164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype.
    McDermott JH; Wolf J; Hoshitsuki K; Huddart R; Caudle KE; Whirl-Carrillo M; Steyger PS; Smith RJH; Cody N; Rodriguez-Antona C; Klein TE; Newman WG
    Clin Pharmacol Ther; 2022 Feb; 111(2):366-372. PubMed ID: 34032273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.
    Tan-Koi WC; Lim ES; Teo YY
    Pharmacogenomics J; 2017 Mar; 17(2):121-127. PubMed ID: 26902540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding.
    Macías Y; Gómez Tabales J; García-Martín E; Agúndez JAG
    Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):319-332. PubMed ID: 32187502
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y
    Sibbing D; Aradi D; Alexopoulos D; Ten Berg J; Bhatt DL; Bonello L; Collet JP; Cuisset T; Franchi F; Gross L; Gurbel P; Jeong YH; Mehran R; Moliterno DJ; Neumann FJ; Pereira NL; Price MJ; Sabatine MS; So DYF; Stone GW; Storey RF; Tantry U; Trenk D; Valgimigli M; Waksman R; Angiolillo DJ
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1521-1537. PubMed ID: 31202949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
    Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
    Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
    Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
    Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
    Naujokaitis D; Asmoniene V; Kadusevicius E
    Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
    Jin Y; Borell H; Gardin A; Ufer M; Huth F; Camenisch G
    Eur J Clin Pharmacol; 2018 Apr; 74(4):455-464. PubMed ID: 29273968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
    Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
    Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.
    Smith CJ; Ryckman KK; Bahr TM; Dagle JM
    Pediatr Res; 2017 Nov; 82(5):776-780. PubMed ID: 28609430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.
    Alqasrawi MN; Al-Mahayri ZN; Alblooshi H; Alsafar H; Ali BR
    Curr Vasc Pharmacol; 2024; 22(3):218-229. PubMed ID: 38284696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
    Cavallari LH; Beitelshees AL; Blake KV; Dressler LG; Duarte JD; Elsey A; Eichmeyer JN; Empey PE; Franciosi JP; Hicks JK; Holmes AM; Jeng L; Lee CR; Lima JJ; Limdi NA; Modlin J; Obeng AO; Petry N; Pratt VM; Skaar TC; Tuteja S; Voora D; Wagner M; Weitzel KW; Wilke RA; Peterson JF; Johnson JA
    Clin Transl Sci; 2017 May; 10(3):143-146. PubMed ID: 28294551
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.